{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:27:11Z","timestamp":1790738831133,"version":"4.1.0"},"reference-count":21,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T00:00:00Z","timestamp":1587945600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Cutaneous adverse events (AEs) are the most prevalent toxicity under checkpoint inhibitors in clinical trials. In \u2018real\u2010life\u2019 conditions of use, skin toxicities under anti\u2010PD\u20101 have not been described to date in a large cohort. The objective of this study was to determine the clinical features of skin toxicities in patients with advanced melanoma receiving anti\u2010PD\u20101 therapy under \u2018real\u2010life\u2019 conditions of use. Secondary objectives were to evaluate the characteristics of patients with skin toxicities and to analyse associated extra\u2010cutaneous toxicities, progression\u2010free survival (PFS) and overall survival (OS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and methods<\/jats:title><jats:p>Advanced melanoma patients treated with nivolumab or pembrolizumab between August 2014 and October 2017 were included. Patients lost to follow\u2010up or receiving anti\u2010PD\u20101 as part of a clinical trial were excluded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One hundred and eighty\u2010nine patients with metastatic melanoma (with 109 men (57.7%) were included. Cutaneous AE occurred in 39 patients (20.6%). The three most prevalent cutaneous AEs were skin eruption (macular\u2013papular or eczematous) (<jats:italic>n\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>18, 9.5%), vitiligo (<jats:italic>n\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>16; 8.5%) and isolated pruritus (<jats:italic>n\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>5, 2.6%). Grade 3\u20134 skin toxicity was diagnosed in five patients (2.6%). Atopy (28.2% vs. 12.0%; <jats:italic>P\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>0.024), hypereosinophilia (20.5% vs. 8.7%; <jats:italic>P\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>0.046), thyroiditis (17.9% vs. 4.7%; <jats:italic>P\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>0.011) and renal toxicity (15.4% vs. 4%; <jats:italic>P\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>0.019) were significantly associated with cutaneous AE. Patients with skin eruption (log\u2010rank\u00a0=\u00a00.001), vitiligo (log\u2010rank\u00a0=\u00a00.001) and any type of cutaneous AE (log\u2010rank\u00a0&lt;\u00a00.001) had a better overall survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Cutaneous AEs are frequent and often manageable toxicity and were a predictor of tumour response in melanoma patients under anti\u2010PD\u20101 therapy in this cohort.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.16311","type":"journal-article","created":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T14:56:55Z","timestamp":1582210615000},"page":"2096-2105","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Cutaneous adverse events: a predictor of tumour response under anti\u2010<scp>PD<\/scp>\u20101 therapy for metastatic melanoma, a cohort analysis of 189 patients"],"prefix":"10.1111","volume":"34","author":[{"given":"L.","family":"Bottlaender","sequence":"first","affiliation":[{"name":"Department of Dermatology ImmuCare Cancer Research Centre of Lyon Centre Hospitalier Lyon Sud Lyon 1 University Pierre B\u00e9nite Cedex France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2366-6238","authenticated-orcid":false,"given":"M.","family":"Amini\u2010Adle","sequence":"additional","affiliation":[{"name":"Department of Dermatology ImmuCare Cancer Research Centre of Lyon Centre Hospitalier Lyon Sud Lyon 1 University Pierre B\u00e9nite Cedex France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Maucort\u2010Boulch","sequence":"additional","affiliation":[{"name":"Service de Biostatistique \u2010 Bioinformatique P\u00f4le Sant\u00e9 Publique Hospices Civils de Lyon Lyon France"},{"name":"Universit\u00e9 de Lyon Lyon France"},{"name":"Universit\u00e9 Lyon 1 Villeurbanne France"},{"name":"CNRS, UMR5558 Laboratoire de Biom\u00e9trie et Biologie \u00c9volutive \u00c9quipe Biostatistique\u2010Sant\u00e9 Villeurbanne France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Robinson","sequence":"additional","affiliation":[{"name":"DRCI Hospices Civils de Lyon Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1995-2434","authenticated-orcid":false,"given":"L.","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Dermatology ImmuCare Cancer Research Centre of Lyon Centre Hospitalier Lyon Sud Lyon 1 University Pierre B\u00e9nite Cedex France"},{"name":"Cancer Research Center of Lyon Claude Bernard Lyon 1 University Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Dalle","sequence":"additional","affiliation":[{"name":"Department of Dermatology ImmuCare Cancer Research Centre of Lyon Centre Hospitalier Lyon Sud Lyon 1 University Pierre B\u00e9nite Cedex France"},{"name":"Service de Biostatistique \u2010 Bioinformatique P\u00f4le Sant\u00e9 Publique Hospices Civils de Lyon Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,4,27]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.1389"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0336-3"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-018-0628-3"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.05.003"},{"key":"e_1_2_6_8_1","first-page":"12","article-title":"Characterisation and management of dermatologic adverse events to agents targeting the PD\u20101 receptor","volume":"2016","author":"Belum VR","year":"1990","journal-title":"Eur J Cancer Oxf Engl"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.01.011"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000154"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.05.035"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.1916"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0123-3"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.2.166"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201444778"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e318247a4e7"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800013"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2017.10.015"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.10.029"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1136"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.2707"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.4756"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.16311","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.16311","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.16311","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.16311","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T02:23:53Z","timestamp":1693707833000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.16311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,27]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1111\/jdv.16311"],"URL":"https:\/\/doi.org\/10.1111\/jdv.16311","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,27]]},"assertion":[{"value":"2019-08-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}